3E Biotech Inc – Trademark Portfolio

Entity Type: 03

3E Biotech Inc holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 21 (Housewares) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include 3E. The owner is based in Irvine, CA.

2 North Cove

Irvine, CA 92604

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

3E
3E
Registered 2021
3E
3E
Registered 2021

Trademark Classifications

3E Biotech Inc's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

21
Housewares (1 filing)

Household or kitchen utensils and containers; combs and sponges; brushes

16
Paper Goods (1 filing)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

Frequently Asked Questions

How many trademarks does 3E Biotech Inc have?

3E Biotech Inc has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does 3E Biotech Inc file in?

3E Biotech Inc files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 21 (Housewares), Class 16 (Paper Goods). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are 3E Biotech Inc's most well-known trademarks?

3E Biotech Inc's registered trademark portfolio includes well-known marks such as 3E. These are among 2 currently registered trademarks in the portfolio.

What is 3E Biotech Inc's trademark registration success rate?

3E Biotech Inc has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.